Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190853 · ClinicalTrials.gov registry record · Phase 3
Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT00190853 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 93 participants.
The verdict
NCT00190853, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
Biomechanical and electrophysiological effects of duloxetine in the treatment of women with urinary stress incontinence
Interventions
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190853
The ClinicalTrials.gov registry entry for NCT00190853 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Duloxetine is the first listed.
NCT00190853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190853 about?
NCT00190853 is a clinical study titled "Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence". Biomechanical and electrophysiological effects of duloxetine in the treatment of women with urinary stress incontinence
What is the current status of trial NCT00190853?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2005-01. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00190853?
The interventions under investigation include: Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00190853?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.